Home > Boards > US Listed > Medical - Drugs > Albireo (ALBO)

ALBO up 12%+ on EMA (PRIME) acceptance

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
djpope Member Profile
 
Followed By 11
Posts 688
Boards Moderated 0
Alias Born 12/21/04
160x600 placeholder
Albireo Recognizes PFIC Awareness Day and Highlights Urgent Needs of Progressive Familial Intrahepatic Cholestasis Families GlobeNewswire Inc. - 10/3/2019 8:00:00 AM
Albireo Announces Presentations at NASPGHAN 2019 Annual Meeting GlobeNewswire Inc. - 9/30/2019 9:23:25 AM
Albireo to Participate in Upcoming Investor Conferences GlobeNewswire Inc. - 9/3/2019 8:30:00 AM
Securities Registration: Employee Benefit Plan (s-8) Edgar (US Regulatory) - 8/8/2019 9:21:17 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/8/2019 8:31:04 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/8/2019 8:08:44 AM
Albireo Reports Second Quarter 2019 Financial Results GlobeNewswire Inc. - 8/8/2019 7:30:00 AM
Albireo to Present at Wedbush PacGrow Healthcare Conference GlobeNewswire Inc. - 8/6/2019 8:30:00 AM
Albireo to Report Second Quarter 2019 Financial Results and Host Conference Call and Webcast GlobeNewswire Inc. - 8/1/2019 8:30:00 AM
Albireo Provides Mid-Year Clinical Development Update GlobeNewswire Inc. - 7/9/2019 4:05:00 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/25/2019 5:22:59 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/25/2019 5:01:51 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/25/2019 4:57:01 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/25/2019 4:54:48 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/25/2019 4:50:23 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/25/2019 4:49:07 PM
Albireo Announces Launch of “PFIC Voices” GlobeNewswire Inc. - 6/20/2019 8:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/18/2019 4:02:18 PM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 6/7/2019 1:38:51 PM
Data on Albireo’s Odevixibat Presented at 2019 European Society for Paediatric Gastroenterology, Hepatology and Nutrition (... GlobeNewswire Inc. - 6/7/2019 7:00:00 AM
Albireo to Present at Investor Conferences in June GlobeNewswire Inc. - 5/29/2019 7:30:00 AM
Albireo Announces Data on Pediatric Cholestatic Liver Diseases to be Presented at the 2019 ESPGHAN Annual Meeting GlobeNewswire Inc. - 5/23/2019 7:30:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/9/2019 10:10:52 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/9/2019 7:48:30 AM
Albireo Reports First Quarter 2019 Financial Results GlobeNewswire Inc. - 5/9/2019 7:30:00 AM
djpope   Tuesday, 11/15/16 04:40:36 PM
Re: None
Post # of 2110 
ALBO up 12%+ on EMA (PRIME) acceptance

First News from newly merged Company getting some well deserved attention.

Best to All dp

http://ir.albireopharma.com/releasedetail.cfm?ReleaseID=999534

Albireo’s Lead Product Candidate for Orphan Pediatric Liver Disease Accepted Into European Medicines Agency’s PRIME Program
Program designed to speed up evaluation of investigational medicines for diseases with unmet medical need

BOSTON, Nov. 15, 2016 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (NASDAQ:ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced today that its lead product candidate, A4250, has been granted access to the PRIority MEdicines (PRIME) program of the European Medicines Agency (EMA) for the treatment of progressive familial intrahepatic cholestasis (PFIC).

“PFIC is a highly debilitating genetic liver disorder that is life altering for affected children and their families,” said Ron Cooper, President and Chief Executive Officer of Albireo. “There is an urgent need for an effective pharmacological treatment for PFIC, as there are currently no approved drug options in the United States or Europe. A4250’s acceptance into the PRIME program serves as validation of its promise to meet that need. We look forward to collaborating with the EMA on the development plan for A4250, as well as the potential accelerated assessment of A4250 in Europe.”

The PRIME program was launched by the EMA to provide enhanced support to developers of investigational medicines that target an unmet medical need, with a focus on those that may offer a major therapeutic advantage over existing treatments or address a disease with no current treatment option. The program is designed to provide early engagement with the EMA to optimize development plans and speed up evaluation, with the goal of helping patients benefit as early as possible from therapies that may significantly improve their quality of life. As of August 2016, only 13 out of 57 requests for PRIME eligibility had been accepted into the program. Having been accepted into the program, A4250 may be eligible for accelerated assessment of a potential future marketing authorization application (MAA) in Europe.

A4250 is currently being evaluated in children with chronic cholestasis in a Phase 2 clinical trial that is intended to support a potentially pivotal clinical trial in PFIC planned to be conducted in the United States and Europe. Albireo anticipates meeting with the U.S. Food and Drug Administration (FDA) regarding the planned PFIC trial in the first quarter of 2017.

About A4250
A4250 is a first-in-class product candidate in development for progressive familial intrahepatic cholestasis (PFIC) and potentially other orphan pediatric cholestatic liver diseases. A4250 is a highly potent and selective inhibitor of the ileal bile acid transporter (IBAT), has minimal systemic exposure and acts locally in the gut. A4250 is currently being evaluated in children with chronic cholestasis in a Phase 2 clinical trial that is intended to support a potentially pivotal clinical trial in PFIC.

About Progressive Familial Intrahepatic Cholestasis
Progressive familial intrahepatic cholestasis (PFIC) is a rare genetic disorder that causes progressive, life-threatening liver disease, which may start early after birth or at a young age and rapidly progress to end-stage liver disease. Three alternative gene defects have been identified that correlate to three separate PFIC subtypes, known as types 1, 2 and 3. The precise prevalence of PFIC is unknown, but PFIC has been estimated to affect between one in every 50,000 to 100,000 children born worldwide.

PFIC is commonly associated with elevated serum bile acids. Prominent symptoms of PFIC include pruritus, which is associated with severe sleep disturbance and diminished overall quality of life, and poor growth. First-line treatment in PFIC is typically off-label ursodeoxycholic acid (UDCA). Notwithstanding treatment with UDCA, many PFIC patients will require partial external biliary diversion (PEBD) surgery and ultimately liver transplantation. Although success rates vary, published third-party studies have shown that PEBD surgery can slow, and in some cases stop, the progression of liver disease and lead to reduced pruritus and improved sleep.

About Albireo
Albireo Pharma is a clinical-stage biopharmaceutical company focused through its operating subsidiary on the development of novel bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. Albireo’s clinical pipeline includes two Phase 2 product candidates and one Phase 3 product candidate. Albireo was spun out from AstraZeneca in 2008.

Albireo Pharma is located in Boston, Massachusetts, and its key operating subsidiary is located in Gothenburg, Sweden. For more information on Albireo, please visit www.albireopharma.com.


Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist